Trabectedin is primarily used in the treatment of advanced soft tissue sarcoma, particularly when other treatments have failed. It is effective in targeting specific cancer cells by interfering with their DNA repair mechanisms, leading to cell death. Additionally, it is used in the treatment of relapsed ovarian cancer, often in combination with other therapies. Its unique mechanism of action makes it a valuable option for patients with limited treatment alternatives. Trabectedin is administered intravenously under medical supervision to manage its potential side effects, such as liver toxicity and myelosuppression.